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Abstract
Background: Australia has increased coverage of antiretroviral treatment (ART) over the past decade, reaching 73%
uptake in 2014. While ART reduces AIDS-related deaths, accumulating evidence suggests that it could also bolster
prevention efforts by reducing the risk of HIV transmission (‘treatment as prevention’). While promising, evidence of
community-level impact of treatment as prevention on reducing HIV incidence among gay and bisexual men is
limited. We describe a study protocol that aims to determine if scale up of testing and treatment for HIV leads to a
reduction in community viraemia and, in turn, if this reduction is temporally associated with a reduction in HIV
incidence among gay and bisexual men in Australia’s two most populous states.
Methods: Over the period 2009 to 2017, we will establish two cohorts making use of clinical and laboratory data
electronically extracted retrospectively and prospectively from 73 health services and laboratories in the states of New
South Wales and Victoria. The ‘positive cohort’ will consist of approximately 13,000 gay and bisexual men (>90% of all
people living with HIV). The ‘negative cohort’ will consist of at least 40,000 HIV-negative gay and bisexual men
(approximately half of the total population). Within the negative cohort we will use standard repeat-testing methods to
calculate annual HIV incidence. Community prevalence of viraemia will be defined as the proportion of men with a
viral load ≥200RNA copies/mm3, which will combine viral load data from the positive cohort and viraemia estimates
among those with an undiagnosed HIV infection. Using regression analyses and adjusting for behavioural and
demographic factors associated with infection, we will assess the temporal association between the community
prevalence of viraemia and the incidence of HIV infection. Further analyses will make use of these cohorts to assess
incidence and predictors of treatment initiation, repeat HIV testing, and viral suppression.
Discussion: This study will provide important information on whether ‘treatment as prevention’ is associated with a
reduction in HIV incidence at a community level among gay and bisexual men.
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Background
Since 1996, combination antiretroviral therapy (ART) for
HIV infection has been used to treat HIV by reducing the
progression to AIDS and preventing AIDS-related deaths.
In recent years, ART has been acknowledged as a key bio-
medical component in reducing onward HIV transmission.
Known as ‘treatment as prevention’, the potential for this
public health approach to control HIV transmission was
evident in the landmark HIV Prevention Trials Network
(052) randomised control trial, which in 2011 observed a
96% reduction in HIV transmission to heterosexual part-
ners of HIV-positive individuals allocated to early ART
compared with those with delayed therapy [1]. More re-
cently, observational cohorts of both same and opposite
sex couples have provided further supporting evidence,
with no linked HIV transmissions among those with sus-
tained viral suppression despite thousands of acts of con-
domless sex [2, 3]. These findings have formed the basis of
international recommendations to employ treatment as
prevention as an additional strategy to eliminate HIV [4].
For treatment as prevention to have greatest impact,
HIV testing and treatment coverage must be high and
treatment must be initiated soon after an infection is di-
agnosed [5]. National estimates from 2014 showed that
73% of people diagnosed with HIV in Australia were on
ART [6] and observational research suggests that treat-
ment coverage has increased over time [7]. Such in-
creases in treatment coverage likely reflect changes to
HIV treatment guidelines. While earlier guidelines only
recommended ART initiation for people with CD4 cell
count below 350 cells/mm3 in 2012 they were updated
to include consideration for those with counts below
500 cells/mm3 and most recently recommended treat-
ment initiation as soon as possible after diagnosis inde-
pendent of CD4 cell count [8]. Additionally, a number of
policy and structural barriers to HIV treatment were ad-
dressed, including the removal of CD4 cell count criteria
for medication reimbursement through the national
health scheme [9] and in the state of New South Wales
the removal of upfront co-payments associated with
treatment dispensing [10].
Alongside treatment, efforts have been made to in-
crease HIV testing in Australia through a number large-
scale health promotion campaigns and new initiatives to
improve access to testing services. Community surveys
of gay and bisexual men in 2014 found that 90% had
ever received an HIV test with two-thirds tested within
the previous year, proportions that have been generally
stable over the past ten years [11]. Among men at high-
est risk of infection, Australian guidelines recommend at
least six-monthly HIV testing [12] but clinical data show
only about half of higher-risk men in 2014 returned for
a follow-up test within six months (up from 40% in
2009) [13]. Thus, there have been some improvements
in HIV testing among gay and bisexual men but to a
lesser degree than for treatment.
Despite improvements in HIV treatment and testing
coverage, annual HIV notifications in Australia increased
by 22% between 2004 and 2012 [6]. In response, many
Australian jurisdictions moved to expand ‘treatment as
prevention’ initiatives and in 2014 all jurisdictional
health ministers committed to a target of virtual HIV
elimination by 2020. In recent years, there has been an
increased focus on testing and treatment initiatives, im-
plemented through partnerships between governments,
clinicians, community organisations and researchers.
These changes represent a major effort nationally to ad-
vance treatment as prevention.
This paper describes a study titled ‘TAIPAN’ (Treat-
ment with Antiretrovirals and their Impact on Positive
And Negative Men), which aims to establish two large
longitudinal cohorts between 2009 and 2017 to evaluate
if the scale up HIV testing and treatment leads to a re-
duction in community viraemia and if this reduction is
temporally associated with a reduction in HIV incidence
among gay and bisexual men.
Methods
Study design
This study will involve a longitudinal cohort design
using de-identified, electronic medical records extracted
for the period 1 January 2009 to 31 December 2017.
Aims
The primary aim of the study is to determine the tem-
poral association between the community prevalence of
HIV viraemia and the incidence of HIV infection among
gay and bisexual men at a community-level. The second-
ary aims are: i) to assess the association between changes
in guidelines and policies and earlier uptake of HIV
treatment among gay and bisexual men, ii) to identify in-
cidence and predictors of repeat HIV testing among
HIV negative gay and bisexual men, and iii) to identify
incidence and predictors of supressed HIV viral load
among HIV positive gay and bisexual men.
Setting
Two study cohorts will be established in the two Austra-
lian states where approximately 65% of gay and bisexual
men in Australia live: New South Wales (population
~7.6 million) and Victoria (population ~5.9 million).
Cohorts
Study cohorts will be established using de-identified data
extracted from electronic patient medical records. These
data will be collected via an existing health sentinel sur-
veillance network of clinics and laboratories known as
the Australian Collaboration for Coordinated Enhanced
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Sentinel Surveillance of Sexually Transmissible Infections
and Blood Borne Viruses (ACCESS). The existing net-
work will be expanded from 50 health services and path-
ology laboratories in New South Wales and Victorian to
a total of 73, including: 39 publicly-funded sexual health
clinics, 10 general practice clinics with medium to high
caseloads of gay and bisexual men (50 or more patients
per year), six hospital HIV outpatient clinics, four
community-led HIV testing services, and 14 private and
public pathology laboratories.
Expansion of the surveillance network will aim to cap-
ture 95% or more of all HIV viral load tests conducted
in both states as well as 100% of HIV diagnoses. These
targets will be achieved by recruiting all laboratories that
conduct HIV viral load testing as well all reference la-
boratories responsible for confirmatory HIV Western
Blot testing. Table 1 outlines the service types and cri-
teria used to identify health services and laboratories
relevant to TAIPAN.
Participants
Using de-identified data extracted from ACCESS sites,
two patient cohorts of gay and bisexual men will be
established: one comprising HIV positive men (‘positive
cohort’) and the other HIV negative men (‘negative co-
hort’). The positive cohort will consist of approximately
13,000 HIV positive gay and bisexual men (approxi-
mately 90% of all gay and bisexual men with HIV in
both states) and the negative cohort will consist of at
least 40,000 HIV negative gay and bisexual men (ap-
proximately half of the population).
Both cohorts will be limited to men aged 16 years and
older for whom there is at least once record indicating a
history of sexual contact with other men. Indicators of
same sex contact can be behavioural (i.e., self-reporting
same sex partners), identity-based (i.e., recorded sexual
orientation as gay or bisexual), or procedural (i.e., collec-
tion of an anal swab for STI testing). The positive cohort
will include patients recorded as HIV positive or those
who receive an HIV diagnosis during the study period.
The negative cohort will include patients whose first
record of HIV testing during the study period is nega-
tive. If during the course of the study a person is diag-
nosed with HIV, they will be reclassified to the positive
cohort. Follow-up during the study period will be based
on records from the participating services as well as the
pathology conducted by participating laboratories.
Study outcomes
Table 2 outlines the study aims, relevant cohorts, and
study outcomes.
Outcome 1
The community prevalence of viraemia is defined as the
proportion of gay and bisexual men (diagnosed and un-
diagnosed) with a viral load of ≥200 RNA copies/mm3.
A viral load of ≥200 was selected as this is a commonly-
used clinical marker of viral suppression and a recent
meta-analysis found no transmission of HIV among indi-
viduals with less than 200 RNA copies/mm3 [14]. Com-
munity prevalence of viraemia was selected as it has
been demonstrated to have the strongest correlation
with HIV incidence over other measures (e.g., mean
viral, treatment coverage) [15]. Our measure of viraemia
will comprise the following four components:
1. Annual prevalence of viraemia: will be calculated
within the positive cohort using the annual
prevalence of viral load test results of ≥200 RNA
copies/mm3 (‘viraemia’) at each patients last viral
load test within a calendar year. We will conduct
sensitivity analyses to include any viral load test
≥200 RNA copies/mm3 in a year and also using a
higher threshold of ≥1000 RNA copies/mm3.
2. Annual prevalence of diagnosed HIV infection
among gay and bisexual men: will be estimated using
population prevalence techniques developed by and
used for Australia’s national HIV surveillance [6].
This approach produces a prevalence estimate using
data on HIV diagnoses from Australia’s National
HIV Registry, adjusting for duplicate entries, deaths,
and migration outside of Australia. For this estimate
we will focus on HIV diagnoses where homosexual
contact is identified as the route of transmission.
3. Annual prevalence of undiagnosed HIV infection
among gay and bisexual men: will be estimated using
standard back-project models [16] and validated
against a separate bio-behavioural survey conducted
in 2013–2014 and to be repeated in 2017 [17].
4. Prevalence of viraemia in gay and bisexual men with
undiagnosed HIV infection: will be calculated using
an estimate of undiagnosed infection obtained from
the back-projection models coupled with the
assumption that all undiagnosed men have viral
loads of ≥200 RNA copies/mm3. We will also
Table 1 Health service and pathology laboratory types and
criteria for the TAIPAN project (n = 73)
Health services Pathology laboratories
Service types Sexual health clinics (n = 39)
General practice clinics (n = 10)
Hospitals (n = 6)
Community-led health services
(n = 4)
Publicly-funded (n = 6)
Private (n = 8)
Criteria (any) ≥50 HIV gay/bisexual men
annually
≥20 HIV positive male patients
annually
≥5 HIV diagnoses annually
Any confirmatory HIV
testing
Any HIV viral load
testing
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consider different viral load levels among undiag-
nosed men by using data from the National HIV
Registry and stratifying viral load at diagnosis by
HIV testing history (i.e., reported time since HIV
test prior to diagnosis).
The combination of these components to generate
community viral load is depicted in Fig. 1. We will cal-
culate an annual community prevalence of viraemia in
gay and bisexual men (diagnosed and undiagnosed) by
combining (i) the annual prevalence of viraemia among
those who have been diagnosed with the estimates of
HIV prevalence, and (ii) the annual prevalence of vir-
aemia among undiagnosed men with the estimates of
undiagnosed infections.
Outcome 2
HIV incidence will be calculated using repeat testing
among the negative cohort, [18] which will consider
patients with two or more HIV tests for whom the first
test was negative. We expect that more than 80% of gay
and bisexual men will have at least two tests over the
study period. An incident infection will be defined as an
HIV diagnosis following a negative test and time at risk
will be calculated as the time between each patient’s first
and last test or a patient’s first test and HIV diagnosis.
The number of incident infections will be divided by the
person time (in years) at risk.
Outcome 3
Data from the positive cohort will also be used to
calculate the incidence of ART initiation (i.e., the
point at which ART is initiated) with the follow-up
period defined as the time after HIV diagnosis (per-
son years of infection). This variable will be restricted
only to men diagnosed with HIV during the study
period.
Table 2 Overview of TAIPAN research aims, study cohorts involved and outcome indicators
Cohort(s) Outcome indicators
Primary aim
Determine the relationship between viraemia and incidence of new






1. Assess the association between changes in guidelines and policies
and earlier uptake of HIV treatment among gay and bisexual men
Positive • Incidence of treatment initiation
2. Identify incidence and predictors of repeat HIV testing among HIV
negative gay and bisexual men
Negative • Incidence of repeat testing (second HIV test within
a 12 month period)
3. Identify incidence and predictors of supressed HIV viral load among
HIV positive gay and bisexual men
Positive • Incidence of viral suppression
Fig. 1 Method for calculating the prevalence of HIV viraemia among diagnosed and undiagnosed gay and bisexual men
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Outcome 4
Data from the negative cohort will be used to calculate
the incidence of repeat diagnostic HIV testing. The inci-
dent event is defined as the point at which a patient
achieves a second HIV test within six weeks to 12 months
of a previous test, with follow-up time defined as the
period between a patient’s first HIV test and last clinical
encounter. Follow-up time will cease if a patient has no
recorded service event of any kind within a two year
period but will resume at the point of future service events
(i.e., reengages with a participating service). Follow-up will
also cease if a patient is diagnosed with HIV.
Outcome 5
Among the positive cohort, the incidence of viral sup-
pression will be calculated. Viral suppression is defined
as two consecutive viral load tests of <200 RNA copies/
mm3 separated by at least three months; the first test
will be taken as the point of suppression for calculating
time. This variable will only be calculated among pa-
tients with no history of previous treatment and will ex-
clude those for whom there is no or only one viral load
test result. We will conduct a sensitivity analysis with a
higher viral load threshold of <1000 RNA copies/mm3.
Covariates
Covariates considered for this study’s analyses will include
patient demographic variables (area of residence, age, indi-
genous status, country of birth, if Australia’s public health
insurance scheme ‘Medicare’ was recorded), clinical infor-
mation (HIV status, STI diagnoses, CD4 cell count and
viral load results, hepatitis B and C co-infection), behav-
ioural information (gender(s) of sexual partner, condom
use, injecting drug use, recent sex work, and sexual
partner numbers) and service provision - related vari-
ables (clinic location - urban vs regional/remote, service
type - general practice, sexual health clinic, hospital,
community-led service). Additionally, treatment informa-
tion and treatment type will be used to assess the use of
HIV antiretrovirals among the negative cohort as pre-
and/or post-exposure prophylaxis (‘PrEP’ and ‘PEP’). The
only variables likely to be missing from a substantial num-
ber of records relate to sexual risk behaviour. For this in-
formation we will draw on records from multiple sources
and use a recorded diagnosis of rectal chlamydia and
gonorrhoea as a surrogate marker of risk [19]. Not all
covariates will be relevant to every analysis.
Data sources
Routine and de-identified patient data will be extracted
from participating service databases, encrypted, and trans-
mitted electronically to a secure server using customised
software known as GRHANITE™ [20]. These extractions
will provide the data relevant to the co-variate and study
outcomes described above. The accuracy of GRHANITE™
has been assessed via internal reliability checks, which
showed that the software correctly classified all pathology
results as positive or negative, and by comparing extracts
with external laboratory data, which found 92–95% con-
cordance [21].
Data quality checks will be conducted biannually and
will include a review of testing numbers to identify
monthly totals exceeding one standard deviation from the
mean. We will also compare data between service types
(i.e., laboratory tests recorded at participating health ser-
vices compared to tests reported by the laboratories rele-
vant to that service) and by comparing the number of
HIV and STI diagnoses recorded in patient medical record
systems to those reported to the jurisdictional health de-
partments. We will also work with participating sites to
compare aggregate outputs produced by their systems in-
ternally with those extracted via GRHANITE™.
The GRHANITE™ extraction software de-identifies pa-
tient data by performing one-way cryptographic trans-
formation of patient details using a secure hash algorithm.
The resultant ‘hashes’ are, therefore, based on patient de-
tails but completely anonymous; they are generated before
data are transmitted from a health service or laboratory to
ensure that potentially identifying details are not extracted
from a participating service [21]. Patient hashes are gener-
ated using four complex algorithms that combine identifi-
able patient details (e.g., given and surnames, date of
birth) to generate unidentifiable strings of code. Using a
combination of one or more of these codes, patients will
be linked probabilistically between and within health ser-
vices and laboratories. Matching patients on four out of
four hashes represents the highest quality match or what
might be considered near certainty while matching on
fewer hashes suggests less certainty. All matches will be
assessed by comparing available demographic data be-
tween services (e.g., widely disparate ages for one patient
between multiple services).
Data analyses
TAIPAN will undertake four separate analyses to address
the study aims (Table 2).
TAIPAN’s primary aim will be addressed by examining
the temporal relationship between community prevalence
of viraemia and incidence of HIV infection in gay and bi-
sexual men. For each year of follow up, the community
prevalence of HIV viraemia as determined by the calendar
year will be entered as an independent variable in the re-
gression. In addition to estimating the effect of commu-
nity prevalence of viraemia, we will control at the
individual level for other demographic, clinical and behav-
ioural determinants of acquisition of new HIV infection,
and recent sexual risk practices. We will use random ef-
fects Poisson models to undertake multi-level analyses
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that will allow us to include group-related variables (com-
munity prevalence of viraemia), individual variables
(demographic, clinical, and behavioural) and time.
The study period will be divided into three-year pe-
riods defined by treatment guidelines and policy. The
first period will encompass 2009–2011 and serve as a
‘before’ treatment as prevention period. The second
period will encompass 2012–2014 and represent a tran-
sition period given that several Australian jurisdictions
began to expand treatment as prevention initiatives dur-
ing this time. And the third period will encompass
2015–2017, representing the full implementation of
treatment as prevention given that early ART initiation
was recommended for both individual and public health
purposes. In regards to time lags, we assume that HIV
incidence is affected by the estimated prevalence of viro-
logical suppression from the preceding year.
The second analysis will examine the temporal rela-
tionship between the three time periods described above
and the incidence of treatment initiation among men
newly diagnosed with HIV (Secondary Aim 1). Using the
study periods described above in a regression analysis,
incidence of treatment initiation among men newly diag-
nosed with HIV will be the outcome variable while con-
trolling for clinical, demographic and behavioural
factors. Given its historical role in determining when to
initiate treatment, CD4 cell count at diagnosis and HIV
viral load will also be included in the multivariate model.
The third analysis will determine incidence and predic-
tors of repeat HIV testing (Secondary Aim 2). To calculate
annual estimates we will allocate follow-up time and the in-
cident of repeat testing (i.e., the point at which a second
test is achieved) to the calendar year in which it occurs.
With this approach it is possible that a patient might
achieve multiple incidents of repeat testing in one calendar
year. In addition to evaluating changes in the incidence of
repeat HIV testing over time, this analysis will employ a re-
gression analysis to identify demographic, behavioural and
clinical factors associated with repeat testing incidence
among gay and bisexual men in the negative cohort.
The fourth analysis will estimate the incidence of viral
suppression among those newly diagnosed and predic-
tors of incidence of viral suppression among the positive
cohort (Secondary Aim 3). This analysis will employ
Cox proportional hazards regression. Further, we will es-
timate the median time from diagnosis to first viral sup-
pression by calendar year among those who are
diagnosed during the study period, stratified by CD4 cell
count at diagnosis. For this analysis and all others, statis-
tical significance will be set at p < 0.05.
Sample size
Sample size calculations are based on the estimated number
of gay and bisexual men diagnosed with HIV annually in
New South Wales and Victoria, [6] and assuming a
modelling-derived 30% reduction in infections to 420 per
year in 2015–2017 (i.e., following the full implementation of
treatment as prevention) [22]. For HIV incidence (Primary
Aim) an estimated 80% of men diagnosed annually will have
some HIV testing history, [23, 24] which equates to 336 in-
cident cases annually and will provide 80% power to detect
annual declines in the incidence rate of at least 20% (hazard
ratio [HR] = 0.80). Regarding treatment initiation (Second-
ary Aim 1), assuming a rate of treatment initiation of 36 per
100 person years (unpublished data from Australian HIV
Observational Database) and an estimated 420 men newly
diagnosed per year, our analysis will have 80% power to de-
tect annual relatives changes in treatment initiation after a
new HIV diagnosis of at least 36% (HR= 1.36).
For repeat HIV testing (Secondary Aim 2), it is esti-
mated that 80% of men in the negative cohort will be
tested at least once annually for HIV [23, 24] and that
25% will have one further test in the year [25]. If the co-
hort contains approximately 40,000 men then this trans-
lates into 8000 repeat testers annually, which will
provide sufficient power to detect at least a 6% annual
increase in the incidence of repeat testing (HR = 1.06).
And for viral suppression (Secondary Aim 3), if we as-
sume that 90% of newly diagnosed men will start treat-
ment [26] then we will have 80% power to detect a 15%
increase in the annual incidence of viral suppression
(HR = 1.15). Trend tests over multiple years will have
greater power as will combining over multiple years as
per the three-year study periods relative to the imple-
mentation of treatment as prevention (see Data
Analyses).
Discussion
Although treatment as prevention has already been shown
to be highly effective among serodiscordant couples, fur-
ther evidence is required to determine its community-
level impact on HIV incidence among gay and bisexual
men. This issue is particularly relevant in the Australian
context, where testing and treatment coverage is high but
where there has been no decline in annual HIV diagnoses
[6]. The two large cohorts established in this study will
provide detailed information on the level of testing and
treatment coverage that can be achieved and, in the turn,
the impact on HIV incidence.
While clinical trial results and modelling studies have
fostered optimism about the treatment as prevention’s
public health potential, the ultimate reduction of inci-
dence may be somewhat less than expected in gay and bi-
sexual men [26]. In Australia, an estimated 12% of people
living with HIV are undiagnosed [6] with the average time
between infection and diagnosis estimated to be between
two and three years [22]. Undiagnosed infections contrib-
ute disproportionately to HIV transmission due to higher
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viral loads and sexual practices [5]. It is, therefore, a key
strength of this study that it will consider the roles of diag-
nosed and undiagnosed HIV in onward transmission
among gay and bisexual men.
There have been only a few community-level studies
of treatment as prevention in gay and bisexual men [27–
30]. A consistent limitation in all these studies is the in-
direct measurement of HIV incidence, calculated either
via mathematical modelling or derived from case notifi-
cations. Although case notifications in a highly tested
population may be close to reflecting incidence, in
Australia nearly a quarter of diagnoses are considered
‘late’ (CD4 cell counts of <350/mm3) [6] and trends in
notifications can be influenced by fluctuations in diag-
nostic testing. One large, community-level study of het-
erosexuals in Africa measured HIV incidence directly
between 2009–2012 and demonstrated a strong correl-
ation between treatment coverage and HIV incidence at
a community-level [31]. These findings, however, cannot
be applied to gay and bisexual men due to population
differences in sexual behaviour and HIV incidence. In
addition, the levels of HIV testing and treatment cover-
age reported in this study were of the levels achieved in
Australia more than a decade ago. Furthermore, any
community-level evaluation of treatment as prevention
must account for potential confounders, including other
prevention and risk reduction strategies and notably the
uptake of PrEP.
Keys strengths of the TAIPAN study design are its
ability to directly measure HIV incidence among gay
and bisexual men, the inclusion of undiagnosed men in
assessing community prevalence of viraemia, and the
large patient cohorts. There are, however, some limita-
tions to consider. First, the HIV negative cohort will in-
clude approximately half of all gay and bisexual men
across both states. Although very large, the cohorts are
unlikely to be fully representative of all gay and bisexual
men in New South Wales and Victoria. We believe it is
reasonable to assume, however, that any temporal re-
lationships and predictors of study outcomes we de-
tect in a cohort of this size will be applicable to the
general population of gay and bisexual men. Second,
during 2016 and 2017 access to PrEP has and will be
expanded in both New South Wales and Victoria.
This parallel prevention initiative may impact on HIV
incidence but we will be able to assess and control
for PrEP uptake in the multivariate analyses through
prescribing data in the HIV negative cohort. Third,
optimism associated with these new prevention strat-
egies may foster changes in men’s sexual behaviour
and potentially undermine the efficacy of treatment as
prevention. As TAIPAN is not able to collect detailed
sexual risk behaviour data, this question will be ex-
plored via separate studies.
The TAIPAN study will contribute to the growing
body of literature that seeks to understand the impact of
HIV treatment as prevention in a range of settings and
population groups. These study outcomes will have im-
plications for policy and practice in resource-rich coun-
tries where the epidemic mainly affects gay and bisexual
men. Considering there have been significant invest-
ments in HIV testing and treatment initiatives in recent
years in Australia and overseas, it is vital to assess the
impact of treatment as prevention on HIV incidence.
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